Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768805 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults
A Phase 2 study, sponsored by Medicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 900
- Enrollment target
NCT02768805 is a Phase 2 study that has completed, run by Medicago. The registered enrollment target is 900 participants.
The verdict
NCT02768805, a Phase 2 study, has completed, sponsored by Medicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 900 participants
- Enrollment target
Study Summary
This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for Biologics Evaluation and Research (CBER) licensure criteria. The study will also help to define the optimal dose, establish potential competitive advantages, and support the design of future studies.
Interventions
- BIOLOGICAL 15 µg/strain of Quadrivalent VLP Vaccine
- BIOLOGICAL 30 µg/strain of Quadrivalent VLP Vaccine
- BIOLOGICAL 15 µg/strain of the licensed quadrivalent vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2016-03-02 |
| Est. Completion | 2016-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02768805
The ClinicalTrials.gov registry entry for NCT02768805 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicago, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 15 µg/strain of Quadrivalent VLP Vaccine is the first listed.
NCT02768805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02768805 about?
NCT02768805 is a clinical study titled "Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults". This Phase 2 Quadrivalent VLP Vaccine study is intended to replicate and extend the immunogenicity and safety results obtained in earlier Phase 1-2 and Phase 2 studies. The study is being conducted to demonstrate that the immunogenicity profile of the Quadrivalent VLP Vaccine meets the US Center for...
What is the current status of trial NCT02768805?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 900 participants. The study started on 2016-03-02. Estimated completion is 2016-11-26.
What interventions are being tested in trial NCT02768805?
The interventions under investigation include: 15 µg/strain of Quadrivalent VLP Vaccine (BIOLOGICAL), 30 µg/strain of Quadrivalent VLP Vaccine (BIOLOGICAL), 15 µg/strain of the licensed quadrivalent vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT02768805?
This trial is sponsored by Medicago, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.